HEM Pharma

HEM파마 · 376270

Industrials Commercial Services · KOSDAQ

Small-cap

Market cap US$244.8M (₩337.8B)

Overview

HEM Pharma develops microbiome-based health and skincare products, using the community of microorganisms that naturally live in and on the human body to create therapeutic candidates and functional cosmetics.

Its products target consumers and patients seeking gut-health solutions and science-backed skincare, and it is listed on KOSDAQ, South Korea's tech and small-cap exchange. The company's portfolio spans live biotherapeutic drug candidates in clinical development and a dermocosmetic line that combines dermatology science with cosmetic formulation, including proprietary ingredients such as a peach-derived probiotic strain.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$9.4M

▼ −13.9% YoY

Operating profit · FY2025

−US$11.3M

Loss widened

Net income · FY2025

−US$17.2M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$3.9M(₩5.3B)	US$10.9M(₩15.1B)	US$9.4M(₩13B)
Operating profit	−US$8.5M(−₩11.8B)	−US$5.6M(−₩7.7B)	−US$11.3M(−₩15.6B)
Net income	−US$8.5M(−₩11.7B)	−US$5.5M(−₩7.6B)	−US$17.2M(−₩23.7B)

Revenue

FY2023US$3.9M
FY2024US$10.9M
FY2025US$9.4M

Operating profit

FY2023−US$8.5M
FY2024−US$5.6M
FY2025−US$11.3M

Net income

FY2023−US$8.5M
FY2024−US$5.5M
FY2025−US$17.2M

Key ratios (FY2025)

ROE

-454.9%

Debt/Eq

894.0%

Op. margin

-120.1%

Net margin

-182.8%

Rev. YoY

▼ −13.9%

Why it matters

HEM Pharma holds a proprietary in-house culture technology called PMAS, which it uses to simulate and study how individual microbiomes interact with drug and cosmetic candidates.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?